Flavonoid–drug interactions: Effects of flavonoids on ABC transporters
Introduction
Flavonoids are a large class of naturally occurring compounds widely present in the green plant world with more than 6500 different compounds described (Harborne and Williams, 2000). In general, these compounds possess a skeleton of a chromane ring with an additional aromatic ring attached at position 2, 3 or 4 (Fig. 1). Based on different substitution and the oxidation status of ring C, flavonoids can be classified into several subclasses including flavones, flavonols, flavonones, flavanols, isoflavones and chalcones (Fig. 1). Flavonoids are also an integral component of our common diet and they are particularly abundant in vegetables, fruits and plant-derived beverages such as wine and tea. For example, grapefruit juice has been shown to contain nearly 200–850 mg/L of total flavonoids, among which naringin is the most abundant (145–638 mg/L) (Ross et al., 2000b) while orange juice mainly contains hesperidin and its content has been shown to be 200–450 mg/L (Erlund et al., 2001, Manach et al., 2003). Soy foods are rich sources for the isoflavones genistein and daidzein and every gram of dry bean contains about 1 mg of these compounds (Reinli and Block, 1996). Green tea and red wine are rich in catechins including epicatechin, epigallocatechin, epicatechin-3-gallate and epigallocatechin-3-gallate, and the content of these compounds in green tea can be as high as 1000 mg/L (Lee et al., 1995). The daily intake of total flavonoids in the U.S. diet has been estimated to be 1 gram (Kuhnau, 1976), but it is likely that this figure may be an overestimation and the actual consumption could be substantially lower.
In nature, most flavonoids exist as glycosides, but the aglycones are generally believed to be absorbed from the gastrointestinal tract after ingestion due to their higher hydrophobicity. The glycosides undergo hydrolysis by glycosidases present in the cells of the gastrointestinal mucosa or secreted by the colonic microflora. This is consistent with the observation that the time to achieve maximum plasma concentrations after oral dosing of genistin or daidzin (glycosides of genistein and daidzein, respectively) is much longer compared to that after oral dosing of the corresponding aglycones (9 h versus 2 h), and that no detectable glycosides were found in plasma (Setchell et al., 2001). Additionally, quercetin but not quercetin glucosides could be detected in ileostomy fluids of patients after ingesting an onion meal containing 10.9 to 51.6 mg of quercetin glucosides with only a trace amount of quercetin, indicating that quercetin glucosides were efficiently hydrolyzed to the aglycone quercetin in the intestine (Walle et al., 2000). However, some controversy exists; the bioavailability of quercetin glucosides from onions was found to be significantly higher than that of the aglycone (Hollman et al., 1995, Hollman et al., 1996), suggesting that glycosides may be also absorbed to some extent. Indeed, quercetin glucosides have been shown to be substrates of the intestinal sodium-dependent glucose transporter (SGLT-1) (Walgren et al., 2000b, Wolffram et al., 2002), implying that these glycosides could be absorbed with the help of SGLT-1. Overall, definitive information regarding flavonoid absorption and bioavailability requires further investigation. Flavonoids undergo extensive intestinal and hepatic glucuronidation and sulfation (Chen et al., 2003, Liu and Hu, 2002) and the predominant circulating chemical species in vivo after an oral dose are these conjugative metabolites. The parent compound concentrations in the systemic circulation are usually below the micromolar range, but their presence is persistent, probably due to the enterohepatic recycling of the conjugated metabolites (Setchell et al., 2001, Walle et al., 2001). However, when a large dose is given intravenously, bypassing first pass metabolism, the plasma concentrations of the parent compounds could reach more than 100 μM (Ferry et al., 1996). Flavonoid metabolism by cytochrome P450 has been observed in in vitro biotransformation studies using rat and human liver microsomes (Hu et al., 2003, Nielsen et al., 1998), but its in vivo significance is, in general, unknown.
In recent years, there has been a resurgence of scientific interest in flavonoids with more than 2000 publications per year containing “flavonoids” as a key word. This is due to the association of these compounds with a wide range of health promoting effects. Numerous studies have indicated that flavonoids have anti-oxidant, anti-carcinogenic, anti-viral, anti-inflammatory and anti-estrogenic or estrogenic activities (Havsteen, 2002, Middleton et al., 2000). High intake of flavonoids has been linked with reduced risk of cancer, cardiovascular diseases, osteoporosis and other age-related degenerative diseases (Havsteen, 2002, Hertog et al., 1993, Huxley and Neil, 2003, Keli et al., 1996, Lee et al., 1991, Middleton et al., 2000, Potter et al., 1998). For example, much of the interest in flavonoids has recently been focused on their anti-cancer properties. Epidemiological studies have suggested an association between flavonoid intake and a reduced risk of certain cancers. The lower rate of breast cancer incidence and mortality observed in Japanese women and women of Japanese origin living in Hawaii has been attributed to their high consumption of the traditional soy product-rich Japanese diet; soy products contain isoflavonoids (Messina et al., 1994). Additionally, a reduced risk of breast cancer incidence has also been associated with a high intake of daidzein and genistein in a German case-control study (Linseisen et al., 2004). In animal studies, administration of flavonoids has been shown to prevent the development and growth of various types of chemical carcinogen-induced or transplanted tumors (Buchler et al., 2003, Kohno et al., 2002, Rice et al., 2002). The proposed mechanisms for these cancer prevention effects are multifaceted, including their anti-oxidant activities, their effects on signal transduction pathways involved in cell proliferation and angiogenesis, as well as their modulation of aromatase activity, a key enzyme involved in estrogen biosynthesis, and the enzymes required for metabolic activation of procarcinogens and the detoxification of carcinogens (Kellis and Vickery, 1984, Middleton et al., 2000)}. In fact, synthetic flavonoid derivatives, flavone acetic acid and flavopiridol, have been evaluated in Phase II clinical trials for their anti-cancer activities (Aklilu et al., 2003, Siegenthaler et al., 1992). In addition to their variety of health-promoting activities, flavonoids themselves are believed to have no or little toxicity and have a long history of human consumption (Middleton et al., 2000). Very large doses of these compounds (up to 500 mg/kg) have been administered to animals, with little or no toxicity reported.
Due to their wide range of health-beneficial activities and their remarkable safety records, numerous herbal preparations containing either flavonoid glycosides or aglycones, including the widely used milk thistle (Silybum marianus) and red clover (trifolium pratense) extracts, are now marketed in various formulations as dietary supplements. The intake of flavonoids after taking these herbal products is likely very high. For example, the recommended dose of chrysin supplements is 1–4 capsules daily and each capsule contains 500 mg chrysin (http://www.herbsmd.com/shop/xq/asp/pid.1646/qx/productdetail.asp); the recommended dose of quercetin supplements is one capsule (620 mg quercetin) daily (http://www.viable-herbal.com/singles/herbs/s914.htm). Daflon 500 is a phlebotonic drug and a vascular protecting agent containing 450 mg diosmin and 50 mg hesperidin per tablet; the suggested dose is up to 6 tablets a day (http://www.medmart.worldmedic.com/Domestic/Memberphar/servier/daflon500.htm) Therefore, the flavonoid concentration, at least in the intestine, could be very high after ingestion of some food and especially, flavonoid-containing supplements, suggesting a potential for drug interactions. Moreover, due to an increased public interest in alternative medicine and disease prevention, the use of herbal preparations for health maintenance has become more popular, and it has been estimated that herbal products are ingested by about 10% or more of the general population and 30–70% of individuals with specific disease states (Duggan et al., 2001, Ni et al., 2002). Thus, the consumption of large doses of flavonoids is frequent, increasing the risk of flavonoid–mediated pharmacokinetic interactions with conventional medication. This concern is relevant, because increasing evidence has indicated that significant or even life-threatening interactions between flavonoid-containing products and conventional drugs can occur. For example, coadministration of grapefruit juice, which contains a large amount of the flavonoid naringin, significantly increased the oral bioavailability of felodipine (Bailey et al., 1993), nimodipine (Fuhr et al., 1998), cyclosporine (Ducharme et al., 1995) and saquinavir (Kupferschmidt et al., 1998), and decreased the oral bioavailability of fexofenadine (Dresser et al., 2002) in human subjects. Silymarin has been reported to increase the clearance of metronidazole and its major metabolite, hydroxy-metronidazole (Rajnarayana et al., 2004). In animals, naringin increases the oral bioavailability of quinine in rats (Zhang et al., 2000) while baicalin and its aglycone baicalein both increase the oral bioavailability of cyclosporine in rats (Lai et al., 2004) and flavone and quercetin can increase the oral bioavailability of paclitaxel in rats (Choi et al., 2004a, Choi et al., 2004b). On the contrary, quercetin and phellamurin decrease the oral bioavailability of cyclosporine in pigs and/or rats (Chen et al., 2002, Hsiu et al., 2002). Considering this accumulating evidence for flavonoid–drug interactions from clinical and animal studies, the frequent presence of high flavonoid content in dietary supplements, and the increasing popularity of many flavonoid-containing herbal products, which do not require FDA approval in the U.S. for marketing, a careful evaluation of the interaction of commonly ingested flavonoids with molecular mechanisms determining drug disposition including absorption, distribution, metabolism and elimination becomes important.
Xenobiotic and endobiotic agents must pass through various biological membrane systems for their absorption, distribution, metabolism and elimination, as well as for binding to their intracelullar targets such as enzymes or receptors to exert their biological functions. The biological membrane system is a lipid bilayer system embedded with numerous proteins including many transporters. Thus, the activities of these transporters are expected to be important determinants for the pharmacokinetics and pharmacodynamics of many important drugs especially those hydrophilic compounds. Knowledge about these transporters has been gained over the past decade, including their functional characteristics, substrate specificities, and their specialized tissue distribution and subcellular localization. Transport proteins play a key role in determining drug absorption, elimination as well as drug entry into some pharmacologically important compartments, such as brain. Therefore, understanding the interaction of flavonoids with these drug transporters will help us understand and predict potential flavonoid–drug interactions. Among these transporters, a group of so called ABC (ATP-binding cassette) transporters including P-glycoprotein, multidrug resistance associated proteins (MRPs) and breast cancer resistance protein (BCRP), have attracted special attention because of their involvement in developing multidrug resistance (MDR) (Litman et al., 2001) and their demonstrated significance in pharmacokinetics and pharmacodynamics. P-glycoprotein, MRPs and BCRP are all plasma membrane efflux transporters, pumping their substrates out of the cells using the energy derived from ATP hydrolysis (Litman et al., 2001). The focus of this overview is to summarize the current findings about the interactions of flavonoids with these efflux transporters, mainly P-glycoprotein, MRP1, MRP2 and BCRP and discuss the potential consequences for flavonoid–drug interactions.
Section snippets
Flavonoid–P-Glycoprotein (ABCB1) interactions
P-glycoprotein is an efflux transporter discovered by Juliano and Ling (1976). The gene-encoding P-glycoprotein consists of two members (MDR1 and MDR3) in humans, and three members (mdr1a, mdr1b and mdr2) in rodents (Chen et al., 1986, Croop et al., 1989, Gros et al., 1988, Lincke et al., 1991). Only human MDR1 and its mouse orthologue mdr1a and mdr1b proteins have drug transport capabilities. Human MDR3 and mouse mdr2 proteins are mainly located in the liver canalicular membranes and are
Flavonoid–MRP1 (ABCC1) interactions
MRP1 is a 190-KD membrane transporter cloned in 1992 (Cole et al., 1992). It is the first member of multidrug resistance associated proteins family that currently consists of nine members. The molecular structure of MRP1 consists a N-terminal segment of five transmembrane domains linked to a typical ABC protein “core” structure with twelve transmembrane domains and two ATP binding sites (Borst et al., 1999, Leslie et al., 2001a). In contrast to P-glycoprotein, which mainly transports
Flavonoid–MRP2 (ABCC2) interactions
MRP2 (cMOAT) is another member of the multidrug resistance associated protein family, sharing a 49% amino acid identity with MRP1 (Leslie et al., 2001a). The molecular structure of MRP2 is very similar to that of MRP1, possessing an extra N-terminal segment of five transmembrane domains linked to a typical ABC protein structure of twelve transmembrane domains and two nucleotide binding domains (Leslie et al., 2001a). This transporter shares a similar but not an identical substrate spectrum with
Flavonoid–BCRP (ABCG2) interactions
BCRP is a recently cloned plasma membrane efflux transporter (Allikmets et al., 1998, Doyle et al., 1998, Miyake et al., 1999) which is also known as ABCP (ABC transporter in placenta) and MXR (Allikmets et al., 1998, Miyake et al., 1999). Human BCRP consists of 655 amino acids with a molecular weight of 72.1 KD (Doyle et al., 1998). Because this transporter has only six transmembrane domains and one N-terminal ATP binding domain (Allikmets et al., 1998), in contrast to a “core” structure of
Conclusion
In conclusion, many flavonoids have been shown to interaction with the efflux transporters especially P-glycoprotein and BCRP in in vitro studies, and the potential consequences for flavonoid–drug interactions due to flavonoid modulation of these efflux transporters have been reported. However, the significance of these flavonoid–efflux transporter interactions in pharmacokinetic interactions has not been unequivocally demonstrated. Since the involvement of other drug transporters and
Note-added-in-proof
The findings of a recent study suggest that quercetin glucuronides represent BCRP substrates (Sesink, A.L., Arts, I.C., de Boer, V.C., Breedveld, P., Schellens, J.H., Hollman, P.C., Russel, F.G., 2005. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol. Jun;67(6):1999–2006.
Acknowledgements
Supported in part by the Susan G. Komen Foundation (BCTR02-1676), the Kapoor Charitable Foundation (University at Buffalo), the Cancer Research and Prevention Foundation and Pfizer Global Research Inc.
References (189)
- et al.
Phase II study of flavopiridol in patients with advanced colorectal cancer
Annals of Oncology
(2003) - et al.
The multidrug resistance protein family
Biochimica et Biophysica Acta
(1999) - et al.
B-ring substituted 5,7-dihydroxyflavonols with high-affinity binding to P-glycoprotein responsible for cell multidrug resistance
Bioorganic and Medicinal Chemistry Letters
(2001) - et al.
cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats
Journal of Biological Chemistry
(1996) - et al.
Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein
Biochemical Pharmacology
(1997) - et al.
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
Cell
(1986) - et al.
Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats
International Journal of Pharmaceutics
(2004) - et al.
Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin
European Journal of Pharmaceutics and Biopharmaceutics
(2004) - et al.
Interaction of the breast cancer resistance protein with plant polyphenols
Biochemical Biophysical Research Communications
(2004) - et al.
Modulation of adriamycin accumulation and efflux by flavonoids in HCT- 15 colon cells. Activation of P-glycoprotein as a putative mechanism
Biochemical Pharmacology
(1994)
Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes
Blood
Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin
Veterinary Parasitology
Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice
Journal of Nutrition
P-glycoprotein-a mediator of multidrug resistance in tumour cells
European Journal of Cancer
Advances in flavonoid research since 1992
Phytochemistry
The biochemistry and medical significance of the flavonoids
Pharmacology and Therapeutics
Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study
Lancet
Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers
American Journal of Clinical Nutrition
Absorption and disposition kinetics of the dietary antioxidant quercetin in man
Free Radical Biology and Medicine
Transepithelial transport of drugs by the multidrug transporter in cultured Madin–Darby canine kidney cell epithelia
Journal of Biological Chemistry
Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats
Life Sciences
Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2)
Life Sciences
Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols
Biochimica et Biophysica Acta
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Biochimica et Biophysica Acta
A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin–Johnson syndrome
Biochemical and Biophysical Research Communications
Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin–Johnson syndrome
Hepatology
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells
Biochemical and Biophysical Research Communications
Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance
Biochimica et Biophysica Acta
The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs
Journal of Pharmaceutical Sciences
Dietary effects on breast-cancer risk in Singapore
Lancet
Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters
Toxicology
Structure of the human MDR3 gene and physical mapping of the human MDR locus
Journal of Biological Chemistry
Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport
Journal of Biological Chemistry
Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2)
Molecular Cancer Therapeutics
The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
Cancer Research
A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
Cancer Research
Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis
Proceedings of the National Academy of Sciences of the United States of America
Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin
Clinical Pharmacology and Therapeutics
A family of drug transporters: the multidrug resistance-associated proteins
Journal of the National Cancer Institute
Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance
Medicinal Research Reviews
Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid
Pancreas
P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
New England Journal of Medicine
Marked decrease of cyclosporin absorption caused by phellamurin in rats
Planta Medicine
Metabolism of flavonoids via enteric recycling: role of intestinal disposition
Journal of Pharmacology and Experimental Therapeutics
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
Science
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells
Cancer Research
Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein
Proceedings of the National Academy of Sciences of the United States of America
Localisation of breast cancer resistance protein in microvessel endothelium of human brain
Neuroreport
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites
Proceedings of the National Academy of Sciences of the United States of America
The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues
Molecular and Cellular Biology
Cited by (239)
pH regulators and their inhibitors in tumor microenvironment
2024, European Journal of Medicinal ChemistryFlavonoids and stilbenoids as a promising arsenal for the management of chronic arsenic toxicity
2022, Environmental Toxicology and PharmacologyPhytochemical profiling, molecular docking, and in vitro anti-hepatocellular carcinoid bioactivity of Suaeda vermiculata extracts
2022, Arabian Journal of ChemistryTherapeutic potential of flavonoids in cancer: ROS-mediated mechanisms
2022, Biomedicine and PharmacotherapyGinkgo biloba leaf extract suppresses intestinal human breast cancer resistance protein expression in mice: Correlation with gut microbiota
2021, Biomedicine and PharmacotherapyCitation Excerpt :In addition, SNPs within regulatory regions of the ABCG2 locus have been reported to tissue-specific variability in ABCG2 expression [35]. The major constituents of GLE, flavonoids quercetin and kaempferol, have been reported to inhibit the transport of mitoxantrone, a BCRP substrate, in BCRP-overexpressing MCF-7 and NCI-H460 cells [36]. Song et al. also reported that quercetin inhibited the function of BCRP in vitro and in vivo [37].